258 related articles for article (PubMed ID: 34474219)
21. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
23. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
25. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
26. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
29. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
30. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
31. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Koleva-Kolarova RG; Oktora MP; Robijn AL; Greuter MJW; Reyners AKL; Buskens E; de Bock GH
Cancer Treat Rev; 2017 Apr; 55():16-25. PubMed ID: 28288388
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
33. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
34. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
35. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
[TBL] [Abstract][Full Text] [Related]
36. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M; Awada A; Harter P; Canon JL; Possinger K; Schmidt M; De Grève J; Neven P; Dirix L; Jonat W; Beckmann MW; Schütte J; Fasching PA; Gottschalk N; Besse-Hammer T; Fleischer F; Wind S; Uttenreuther-Fischer M; Piccart M; Harbeck N
Breast Cancer Res Treat; 2012 Aug; 134(3):1149-59. PubMed ID: 22763464
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
40. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
